comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 01:01:33 - browse：917

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Surgeons perform first xenotransplant using CRISPR'd pig kidney

focus

WSS

In utero gene editing: an explainer

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

'Patient friction coefficient' can gauge a clinical trial's patient burden

Adam's Take: Intra

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

The Harvard botanist who searched for psychedelics in the Amazon

Wikipedia

comprehensive

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Medical devices makers are asking for forgiveness, not permission

Guidelines to prevent youth baseball injuries need more muscle

U.K. officials, researchers try to ease path for bespoke genetic treatments

Anesthesiologist group: stop taking Ozempic before surgery

A new nitrogen execution bill also undermines medical licensing

Cancer drug shortages should be causing more outrage

What Kate Middleton's cancer revelation might teach the world

The cancer drug shortage isn’t new — and neither are the solutions

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

With competition flaring, obesity drug hits goal in liver disease study

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Chinese researcher claims birth of first gene

Surgeons perform first xenotransplant using CRISPR'd pig kidney

U.K. officials, researchers try to ease path for bespoke genetic treatments

Texas board proposes rules on abortion law emergency exemption

focus

knowledge

focus

hotspot